期刊文献+

甲型H1N1流感疫苗接种2年后免疫持久性评价 被引量:1

Immunity Durability of Influenza A (H1N1) Vaccine 2 Years After Vaccination
原文传递
导出
摘要 目的评价成都市甲型H1N1流感(甲流)疫苗接种2年后疫苗免疫持久性。方法以2011年接种甲型H1N1流感疫苗1年后HI抗体≥1:40的170人作为观察对象,用微量血凝抑制试验方法测定抗体,计算人群GMT和疫苗保护率。结果甲型H1N1流感疫苗免疫后2年观察对象GMT为1:32.60,较免疫后1年下降72.34%,保护率达70.O%,老年组保护率仅为48.49%。观察对象中免疫后2年有7.06%的人抗体滴度上升。经估算人群2年后保护率为49.23%;而3—11岁组、12~17岁组、18—59岁组、I〉60岁组估算保护率分别为46.96%、69.38%、45.63%和12.58%。结论甲流疫苗免疫后2年抗体大幅降低,人群失去保护屏障,具有保护性抗体的人数大幅减少,特别是老年组基本不具有甲流保护抗体,所有人群需再次接种。 Objective To evaluate the immunity durability of influenza A ( HIN1 ) 2 years after vaccination in Chengdu. Methods Totally 170 people with HI antibodies no less than 1 : 40 one year after immunization were selected for observation and micro - hemagglutination inhibition test was adopted to determine the antibodies, and to calculate the GMT and the protection rate. Results Two years after vaccination, the GMT was 1 : 32. 60 with a declination of 72. 34% compare with one year ago ; the overall protection rate was 70. 0% and for the elderly group, the protection rate was 48.49%. The antibody titer decreased in 7.06% of the subjects two years after the vaccination. The estimated protection rate were 49.23% two years after the vaccination. The estimated protective rates for 3 - 11 age group, 12 - 17 age group, 18 -59 age group and no less than 60 years group were respectively 46. 96%, 69.38%, 45.63% and 12. 58%. Conclusion Two years after the influenza A (H1N1) vaccination, the antibody titers are greatly reduced and thus those with protective antibodies sharply reduced, especially in elderly group, indicating a necessity of revaccinated.
出处 《预防医学情报杂志》 CAS 2014年第6期439-442,共4页 Journal of Preventive Medicine Information
关键词 甲型H1N1流感 疫苗 免疫持久性 influenza A (H1 N1 ) vaccine immunity durability
  • 相关文献

参考文献6

二级参考文献24

  • 1张雪峰,方捍华,赵静,余录根,张艺飓,朱凤才.流行性感冒病毒裂解疫苗临床安全性及免疫原性研究[J].中国计划免疫,2005,11(5):348-351. 被引量:18
  • 2Peiris JS,Poon LL,Guan Y.Emergence of a novel swine-origin influenza A (H1N1) virus in humans[J].N Engl J Med,2009,360:2605-2615.
  • 3Garten RJ,Davis CT,Russell CA,et al.Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans[J].Science,2009,325:197-201.
  • 4Wiley SR,Schooley K,Smolak PJ,et al.Identification and characterization of new member of the TNF family that induces apoptosis[J].Immunity,1995,3 (6):673-682.
  • 5郭元吉.流行性感冒[M].见:黄祯祥.医用病毒学基础及实验技术.北京:科学出版社,1990:661.
  • 6CDC. Use of influenzaA/H1N1 2009 monovalent vaccine: recommen- dations of the Advisory Committee on Immunization Practices( AC1P), 2009[J]. MMWR Recomm Rep, 2009, 58(RR-10) : 1-8.
  • 7European Committee for Proprietary Medicinal Products Guide - line on dossier structure and content for pandemic influenza vaccine marketing anthorisation application ( CPMP/VEG/4717/03 ). European Agency for the Evaluation of MedicinalProduets[ EB/OL]. [2008 - 12 - 18]. ht- tp: //www. emea. europa, eu/pdfs/human/vwp/471703enfin, pdf.
  • 8Cate T, Couch Pt, Parker D, et al. Reactogenicity, immunogenicity and antibody persistance in adults given inactivated influenza virus vaccine - 1978 [ J]. Rev Infect Dis, 1983, 5 : 737-47.
  • 9Centers for Disease Control and Prevention (CDC). Swine influenzaA/H1N1 infection in two children-Southern California, March-April 2009 E J ]. MMWR Morb Mortal Wkly Rep,2009 ,58 (15) :400 -402.
  • 10Centers for Disease Control and Prevention (CDC). Safety of influenzaA ( H1N1 ) 2009 monovalent vaccines-United States, October 1 -November 24,2009[J]. MMWR Morb Mortal Wkly Rep ,2009,58:1351 - 1356.

共引文献8

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部